Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002824 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Primary Brain Tumors
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002824 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine.
The verdict
NCT00002824, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Inserting the gene for herpes virus into a person's cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy using antiviral drugs such as ganciclovir. PURPOSE: Phase I trial to study the effectivenesss of gene therapy in treating patients with primary brain tumors.
Interventions
- PROCEDURE conventional surgery
- DRUG chemotherapy
- DRUG ganciclovir
- BIOLOGICAL gene therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002824
The ClinicalTrials.gov registry entry for NCT00002824 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which conventional surgery is the first listed.
NCT00002824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002824 about?
NCT00002824 is a clinical study titled "Gene Therapy in Treating Patients With Primary Brain Tumors". RATIONALE: Inserting the gene for herpes virus into a person's cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy using antiviral drugs such as ganciclovir. PURPOSE: Phase I trial to study the effectivenesss of gene therapy in treating patients wi...
What is the current status of trial NCT00002824?
This trial is currently completed. It is a Phase 1 study. The study started on 1996-02.
What interventions are being tested in trial NCT00002824?
The interventions under investigation include: conventional surgery (PROCEDURE), chemotherapy (DRUG), ganciclovir (DRUG), gene therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002824?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.